Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 540

1.

How I treat first relapse of myeloma.

Harousseau JL, Attal M.

Blood. 2017 Aug 24;130(8):963-973. doi: 10.1182/blood-2017-03-726703. Epub 2017 Jul 5. Review.

PMID:
28679737
2.

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

Harousseau JL, Avet-Loiseau H.

J Clin Oncol. 2017 Sep 1;35(25):2863-2865. doi: 10.1200/JCO.2017.73.1331. Epub 2017 May 19. No abstract available.

PMID:
28525304
3.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

4.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
5.

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Malard F, Harousseau JL, Mohty M.

Cancer Treat Rev. 2017 Jan;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. Epub 2016 Nov 15. Review.

PMID:
27888768
6.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14.

7.

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Rajkumar SV, Harousseau JL.

Blood. 2016 Dec 15;128(24):2757-2764. Epub 2016 Oct 14. Review.

8.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.

9.

COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE.

Poullié AI, Cognet M, Gauthier A, Clementz M, Druais S, Späth HM, Perrier L, Scemama O, Pichon CR, Harousseau JL.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):37-45. doi: 10.1017/S0266462316000088. Epub 2016 Mar 9.

PMID:
26956455
10.

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M.

Bone Marrow Transplant. 2016 Feb;51(2):267-72. doi: 10.1038/bmt.2015.250. Epub 2015 Dec 7.

PMID:
26642337
11.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Dejoie T, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.

12.

Shaping European Early Dialogues: The Seed Project.

Harousseau J, Pavlovic M, Mouas H, Meyer F.

Value Health. 2015 Nov;18(7):A562. doi: 10.1016/j.jval.2015.09.1830. Epub 2015 Oct 20. No abstract available.

13.

Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry.

Desplantes C, Fremond ML, Beaupain B, Harousseau JL, Buzyn A, Pellier I, Roques G, Morville P, Paillard C, Bruneau J, Pinson L, Jeziorski E, Vannier JP, Picard C, Bellanger F, Romero N, de Pontual L, Lapillonne H, Lutz P, Chantelot CB, Donadieu J.

Orphanet J Rare Dis. 2014 Dec 10;9:183. doi: 10.1186/s13023-014-0183-8.

14.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Harousseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P.

Ann Hematol. 2015 Apr;94(4):663-9. doi: 10.1007/s00277-014-2259-x. Epub 2014 Nov 21.

PMID:
25409914
15.

A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Poullié AI, Gauthier A, Cognet M, Clementz M, Späth HM, Perrier L, Scemama O, Rumeau Pichon C, Harousseau JL.

Value Health. 2014 Nov;17(7):A597. doi: 10.1016/j.jval.2014.08.2062. Epub 2014 Oct 26. No abstract available.

16.

Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Ghabri S, Hamers FF, Josselin JM, Harousseau JL.

Value Health. 2014 Nov;17(7):A441-2. doi: 10.1016/j.jval.2014.08.1160. Epub 2014 Oct 26. No abstract available.

17.

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Rumeau-Pichon C; Health Economics and Public Health Department S, Health Economics and Public Health Committee C, Harousseau JL.

Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.997. Epub 2014 Oct 26. No abstract available.

18.

Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Rumeau-Pichon C; Health Economics and Public Health Department S, Health Economics and Public Health Committee C, Harousseau JL.

Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.996. Epub 2014 Oct 26. No abstract available.

19.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.

J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.

20.

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.

Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, Moreau P, Mechinaud F, Milpied N, Mohty M.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1217-23. doi: 10.1016/j.bbmt.2014.04.021. Epub 2014 Apr 23.

Supplemental Content

Loading ...
Support Center